Regeneron Has Much Good News. Is the Market Paying Attention?

Regeneron Pharmaceuticals Approval of EvkeezaTM for HoFH
Regeneron Pharmaceuticals (REGN) has a series of good news that the market does not seem to be aware of as the stock price has yet to react.  

On February 11, 2021 Regeneron announced that the U.S. FDA has approved the firm’s product EvkeezaTM (evinacumab-dgnb) as an adjunct to . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.